for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Eloxx Pharmaceuticals Inc

ELOX.OQ

Latest Trade

4.51USD

Change

0.56(+14.18%)

Volume

122,643

Today's Range

3.96

 - 

4.98

52 Week Range

1.48

 - 

6.77

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.95
Open
3.99
Volume
122,643
3M AVG Volume
4.50
Today's High
4.98
Today's Low
3.96
52 Week High
6.77
52 Week Low
1.48
Shares Out (MIL)
40.15
Market Cap (MIL)
158.60
Forward P/E
-4.27
Dividend (Yield %)
--

Next Event

Eloxx Pharmaceuticals Inc Annual Shareholders Meeting

Latest Developments

More

Eloxx Pharmaceuticals Reports Third Quarter 2020 Financial And Operating Results And Provides Business Update

Eloxx Pharma Resumes Enrollment In U.S. Phase 2 Clinical Trial In Cystic Fibrosis

Eloxx Pharmaceuticals Reports Q2 Loss Per Share Of $0.20

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Eloxx Pharmaceuticals Inc

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing ribonucleic acid (RNA)-modulating drug candidates, which are designed to be eukaryotic ribosomal selective glycosides (ERSG). It is developing its drug candidates for treating rare and ultra-rare premature stop codon diseases. ELX-02 is its lead investigational drug product candidate. ELX-02 is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development for systemic administration for cystic fibrosis and cystinosis. Its preclinical candidate pool consists of a library of novel ERSG drug candidates identified based on read-through potential and cytoplasmic ribosomal selectivity.

Industry

Biotechnology & Drugs

Contact Info

950 Winter St

WALTHAM, MA

02451-1424

United States

+1.858.9090749

https://www.eloxxpharma.com/

Executive Leadership

Tomer Kariv

Independent Chairman of the Board

Gregory Williams

Chief Executive Officer, Director

Neil S. Belloff

Chief Operating Officer, General Counsel, Corporate Secretary

Stephen MacDonald

Principal Accounting Officer, Vice President - Finance and Accounting, Treasurer

Silvia Noiman

Director

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2018

-1.450

2019

-1.340

2020(E)

-0.925
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
10.52
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
84.49
LT Debt To Equity (MRQ)
51.88
Return on Investment (TTM)
-100.48
Return on Equity (TTM)
-79.37

Latest News

Latest News

BRIEF-Eloxx Pharmaceuticals Says Enrollment In Phase 2 Clinical Trial In Cystic Fibrosis Has Resumed In Israel And Europe

* ENROLLMENT IN PHASE 2 CLINICAL TRIAL IN CYSTIC FIBROSIS HAS BEEN RESUMED IN ISRAEL AND EUROPE AFTER BEING PAUSED TEMPORARILY IN RESPONSE TO THE COVID-19 PANDEMIC

BRIEF-Eloxx Pharmaceuticals Provides Update On The Impact Of Novel Coronavirus On Phase 2 Clinical Trials In Cystic Fibrosis

* ELOXX PHARMACEUTICALS PROVIDES UPDATE ON THE IMPACT OF NOVEL CORONAVIRUS (COVID-19) ON PHASE 2 CLINICAL TRIALS IN CYSTIC FIBROSIS

BRIEF-Eloxx Pharmaceuticals Reports Q4 Loss Per Share $0.29

* ELOXX PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Eloxx Pharmaceuticals Says Board Approved Leadership And Organizational Re-Alignment

* ELOXX PHARMACEUTICALS INC - ON FEB 24, BOARD APPROVED A LEADERSHIP AND ORGANIZATIONAL RE-ALIGNMENT

BRIEF-Eloxx Strengthens Its Commitment To Cystic Fibrosis Through Reallocating Resources

* ELOXX STRENGTHENS ITS COMMITMENT TO CYSTIC FIBROSIS THROUGH REALLOCATING RESOURCES

BRIEF-Eloxx Pharmaceuticals Reports Q1 Loss Per Share $0.31

* ELOXX PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Eloxx Pharmaceuticals Announces Orphan-Drug Designation For ELX-02 For Treatment Of Cystinosis

* ELOXX PHARMACEUTICALS ANNOUNCES FDA GRANT OF ORPHAN-DRUG DESIGNATION FOR INVESTIGATIONAL DRUG ELX-02 FOR TREATMENT OF CYSTINOSIS Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up